

GASTROENTEROLOGY ORDER SET

P: (877) 778-0318 F: (877) 778-0399

Patient Information		
Patient Name:	DOB: I	Phone:
Patient Status: New to Therapy	□ Continuing Therapy Next Treatment Date:	
Patient Weight: lbs. (re	quired) Allergies:	
	Medication Orders	Refills
Diagnosis	Medication Orders	Reillis
□ Crohn's Disease □ Ulcerative Colitis □ Other: ICD-10 Code:	product: For AmeriPharma use only. Brand: Dose: mg/kg Frequency: □ Every weeks □ 0, 2, 6 then every 8 weeks	
	□ Skyrizi initial infusion: 600mg IV at week 0, 4, and 8 □ Skyrizi maintenance: 360 mg SubQ at week 12, and 68 8 weeks thereafter (to be evaluated by AmeriPharma) □ Stelara initial infusion: □ <55kg - 260 mg IV x 1 dose □ 55kg to 85kg - 390mg IV x 1 □ >85kg - 520mg IV x 1 dose □ Stelara maintenance: □ 90 mg SQ 8 weeks after initiand then every 8 weeks □ Tysabri 300mg IV every 4 weeks □ Entyvio 300mg IV at 0, 2, 6 weeks and then Q8 week □ Entyvio 300mg IV every 8 weeks	dose ial infusion
Premedication orders: Tylenol □ 1000mg □ 500mg PO, please choose one antihistamine: □ Diphenhydramine 25mg PO □ Loratadine 10mg PO □ Cetirizine 10mg PO □ Cetirizine 10mg IVP Additional premedications: □ Solu-Medrol mg IVP □ Solu-Cortef mg IVP □ Other: Lab orders: Frequency: □ Every infusion □ Other: □ Yearly TB QFT □ Baseline HepBcAB total Required labs to be drawn by: □ AmeriPharma □ Referring Provider Home biologic IV Ana-kit (adult): Dispense EpiPen 0.3mg IM (2-pack) or compounded syringe, diphenhydramine 50mg IV and PO, NS 10000mL per protocol Home biologic injection Ana-kit (adult): Dispense EpiPen 0.3mg IM (2-pack) per protocol		
Provider Information	Provider's Signature	Data
Provider NPI:	Provider's Signature: Cont	Date:
	(if checked, please list site of care):	dot i 013011.
		City State



COMPREHENSIVE SUPPORT FOR GASTROENTEROLOGY THERAPY

Patient Information		
Patie	ent Name: DOB:	
Req	uired Documentation for Referral Processing & Insurance Approval	
	of a conventional therapy (i.e., 6MP, Azathioprine)? Yes No If yes, which drug(s)?	
L	□ For biologic orders, does the patient have a documented contraindication/intolerance or failed trial to any other biologic (i.e., Humira, Stelara, Cimzia)? □ Yes □ No If yes, which drug(s)?	
□ /;	Include labs and/or test results to support diagnosis If applicable - Last known biological therapy: and last date received: If patient is switching to biologic therapies, please perform a wash-out period of weeks prior to starting ordered biologic therapy. Other medical necessity:	
Reg	juired Pre-Screening (Based on drug therapy)	
- c	TB Screening test completed within 12 months - attach results Required for: Cimzia, Infliximab, Stelara, Entyvio, Skyrizi Positive Negative	
F	Hepatitis B screening test completed (Hepatitis B surface antigen) - attach results Required for: Cimzia, Infliximab □ Positive □ Negative	
F	JCV antibody & TOUCH authorization Required for: Tysabri □ Positive □ Negative	
F *	Labs indicating iron deficiency Required for: Venofer, Injectafer, Monoferric If TB or Hepatits B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)	
doc any	eriPharma Specialty Care will complete insurance verification and submit all required cumentation for approval to the patient's insurance company for eligibility. Our team will notify you if additional information is required. We will review financial responsibility with the patient and referm to any available co-pay assistance as needed. Thank you for the referral.	

Please fax all information to (877) 778-0399 or call (877) 778-0318 for assistance.